This study thoroughly investigated the role of the long non-coding RNA LOXL1-AS1 in the pathogenesis of cholangiocarcinoma (CCA). Through bioinformatics analysis and tissue samples validation, the study found that LOXL1-AS1 was significantly elevated in CCA, with its high expression closely tied to clinical pathological features and prognosis. In vitro and in vivo experiments revealed that LOXL1-AS1 was crucial in regulating CCA cell apoptosis, proliferation, migration, and invasion. Further investigations using FISH, subcellular localization experiments, RNA pull down, and RIP uncovered that LOXL1-AS1 primarily resided in the cytoplasm and influenced CCA progression by modulating the JAK2/STAT3 signaling pathway. Notably, LOXL1-AS1 might regulate the activity of JAK2 through modulating its ubiquitination and degradation. YY1 had also been found to act as an upstream transcription factor of LOXL1-AS1 to impact CCA cell malignancy. These findings shed light on the pivotal role of LOXL1-AS1 in CCA and offered potential directions for novel therapeutic strategies, providing a fresh perspective on tumor pathogenesis.

本研究深入研究了长链非编码RNA LOXL1-AS1在胆管癌（CCA）发病机制中的作用。通过生物信息学分析和组织样本验证，研究发现LOXL1-AS1在CCA中显着升高，其高表达与临床病理特征和预后密切相关。体外和体内实验表明，LOXL1-AS1 在调节 CCA 细胞凋亡、增殖、迁移和侵袭中至关重要。使用 FISH、亚细胞定位实验、RNA pull down 和 RIP 进行的进一步研究发现，LOXL1-AS1 主要存在于细胞质中，并通过调节 JAK2/STAT3 信号通路影响 CCA 进展。值得注意的是，LOXL1-AS1 可能通过调节 JAK2 的泛素化和降解来调节 JAK2 的活性。YY1 还被发现作为 LOXL1-AS1 的上游转录因子来影响 CCA 细胞恶性肿瘤。这些发现揭示了 LOXL1-AS1 在 CCA 中的关键作用，并为新的治疗策略提供了潜在的方向，为肿瘤发病机制提供了新的视角。